Corvus Pharmaceuticals Inc (NASDAQ:CRVS) CEO Richard A. Md Miller purchased 9,212 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The stock was bought at an average cost of $3.37 per share, with a total value of $31,044.44. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of NASDAQ:CRVS traded down $0.15 during midday trading on Friday, hitting $3.49. 590 shares of the stock were exchanged, compared to its average volume of 69,996. The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.39 and a current ratio of 12.39. Corvus Pharmaceuticals Inc has a 12 month low of $3.22 and a 12 month high of $13.91.
Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.40) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.40). On average, research analysts forecast that Corvus Pharmaceuticals Inc will post -1.61 earnings per share for the current year.
A number of research analysts have issued reports on CRVS shares. Zacks Investment Research cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, March 28th. Wedbush decreased their target price on Corvus Pharmaceuticals from $19.00 to $11.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 13th. Finally, Roth Capital started coverage on Corvus Pharmaceuticals in a research report on Wednesday, May 29th. They issued a “buy” rating and a $6.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $9.19.
Institutional investors have recently bought and sold shares of the stock. Raymond James Trust N.A. acquired a new position in shares of Corvus Pharmaceuticals in the first quarter worth approximately $53,000. Paloma Partners Management Co acquired a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth approximately $58,000. Rhumbline Advisers lifted its stake in shares of Corvus Pharmaceuticals by 44.1% in the fourth quarter. Rhumbline Advisers now owns 18,203 shares of the company’s stock worth $67,000 after acquiring an additional 5,570 shares during the period. State of Wisconsin Investment Board lifted its stake in shares of Corvus Pharmaceuticals by 29.4% in the first quarter. State of Wisconsin Investment Board now owns 18,500 shares of the company’s stock worth $74,000 after acquiring an additional 4,200 shares during the period. Finally, Prudential Financial Inc. lifted its stake in shares of Corvus Pharmaceuticals by 15.0% in the fourth quarter. Prudential Financial Inc. now owns 21,545 shares of the company’s stock worth $79,000 after acquiring an additional 2,805 shares during the period. 84.46% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Corvus Pharmaceuticals Inc (NASDAQ:CRVS) CEO Acquires $31,044.44 in Stock” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2019/06/14/corvus-pharmaceuticals-inc-nasdaqcrvs-ceo-acquires-31044-44-in-stock.html.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Featured Article: Front-End Load
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.